Bioymifi

CAS No. 1420071-30-2

Bioymifi( Bioymifi )

Catalog No. M11756 CAS No. 1420071-30-2

Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 72 In Stock
2MG 40 In Stock
5MG 61 In Stock
10MG 104 In Stock
25MG 214 In Stock
50MG 377 In Stock
100MG 549 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Bioymifi
  • Note
    Research use only, not for human use.
  • Brief Description
    Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis
  • Description
    Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Bioymifi
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    DR5
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1420071-30-2
  • Formula Weight
    494.32
  • Molecular Formula
    C22H12BrN3O4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    O=C1NC(C2=C1C=CC(C3=CC=C(/C=C(SC(N4C5=CC=C(Br)C=C5)=N)/C4=O)O3)=C2)=O
  • Chemical Name
    (Z)-5-(5-[(3-[4-Bromophenyl]-2-imino-4-oxothiazolidin-5-ylidene)methyl]furan-2-yl)isoindoline-1,3-dione

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Wang G, et al. Nat Chem Biol. 2013 Feb;9(2):84-9.
molnova catalog
related products
  • Menthone

    Menthone has anti-inflammary activity it can suppress the lipopolysaccharide (LPS)-induced proinflammatory cytokines interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha)as well as nuclear factor kappaB (NF-kB).

  • Teneliximab

    Teneliximab (BMS 224819) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interactions.

  • Pomalidomide

    A potent inhibitor of TNF-α production; inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.